Arylsulfatase A gene therapy (Regenxbio)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameArylsulfatase A gene therapy (Regenxbio)
Drug Alias Name芳基硫酸酯酶的基因治疗 - Regenxbio
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionARSA gene transference
TargetsCerebroside-sulfatase
Therapy Area/IndicationsLeukodystrophy, Metachromatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsLeukodystrophy, Metachromatic

Other Information

ATC CodeN/A
Related LinksN/A